125 related articles for article (PubMed ID: 18779749)
21. Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells.
Bae SM; Kim YW; Kwak SY; Kim YW; Ro DY; Shin JC; Park CH; Han SJ; Oh CH; Kim CK; Ahn WS
Cancer Sci; 2007 May; 98(5):747-52. PubMed ID: 17425690
[TBL] [Abstract][Full Text] [Related]
22. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
23. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
25. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
26. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
27. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
Seo N; Tokura Y; Takigawa M; Egawa K
J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
[TBL] [Abstract][Full Text] [Related]
28. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
29. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
[TBL] [Abstract][Full Text] [Related]
30. [Probability of vaccine therapy for pancreas cancer].
Takahashi M; Togou S; Yamaoka H; Ichikawa H; Shimada H; Cheever MA
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1676-8. PubMed ID: 8886043
[TBL] [Abstract][Full Text] [Related]
31. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
32. Effective antitumoral immune responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model.
Eisold S; Antolovic D; Schmidt J; Wiessner R; Klar E; von Knebel-Doeberitz M; Linnebacher M
Eur Surg Res; 2006; 38(6):513-21. PubMed ID: 17028434
[TBL] [Abstract][Full Text] [Related]
33. Avitalized bacteria mediate tumor growth control via activation of innate immunity.
Klier U; Maletzki C; Göttmann N; Kreikemeyer B; Linnebacher M
Cell Immunol; 2011; 269(2):120-7. PubMed ID: 21463858
[TBL] [Abstract][Full Text] [Related]
34. Current immunotherapeutic strategies in pancreatic cancer.
Plate JM
Surg Oncol Clin N Am; 2007 Oct; 16(4):919-43, xi. PubMed ID: 18022552
[TBL] [Abstract][Full Text] [Related]
35. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
36. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
37. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity.
Turnquist HR; Lin X; Ashour AE; Hollingsworth MA; Singh RK; Talmadge JE; Solheim JC
Int J Oncol; 2007 Mar; 30(3):631-9. PubMed ID: 17273764
[TBL] [Abstract][Full Text] [Related]
38. Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer.
Cubas R; Zhang S; Li M; Chen C; Yao Q
J Immunother; 2011 Apr; 34(3):251-63. PubMed ID: 21389873
[TBL] [Abstract][Full Text] [Related]
39. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
40. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
